glp-1 receptor Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Science Behind GLP 1 GIP

Hashimoto's thyroiditis is an autoimmune condition causing hypothyroidism, affecting approximately 5% of Americans and frequently associated with weight gain and metabolic complications

NichollsSJBhattDLBuseJBPratoSDKahnSELincoffAMet alComparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics

van Greevenbroek MM, Schalkwijk CG, Stehouwer CD

Emerging advancements in anti-obesity treatments include the development of oral formulations [23] and once-monthly [24] dosing regimens, which aim to improve patient adherence and convenience, simplifying the integration of these therapies into daily life

Blog Oral glp1 in obesity treatment The Oral GLP-1 Revolution: How Pill-Based Drugs Are Reshaping the Obesity Treatment Space Table of Contents Summary The obesity drug landscape is shifting from injectable GLP-1s to oral pill-based treatments, marking a major turning point in pharmacotherapy

Examining Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists for Central Nervous System Disorders: Proceedings of a Workshop